The Medical Briefing  Nephrology

Enteric-coated budesonide and sparsentan in IgA nephropathy, SIADH, kidney replacement in cardiogenic shock

Retrospective no. 3/12

The essentials in four articles

■ Glomerular disease
168 patients treated for 9 months: albuminuria −66% and GFR +5 mL/min/1.73 m², benefit maintained when GFR is < 35. No serious adverse event. An accessible option, to be confirmed by controlled trials against targeted-release budesonide.

■ Glomerular disease
38 patients: sustained fall in proteinuria (about 8% per month), GFR slope of −2.5 mL/min/1.73 m²/year. Hematuria and higher systolic blood pressure predict response; 10.5% discontinuations. Retrospective data, consistent with the PROTECT trial.

■ Clinical nephrology
88 patients: fluid restriction < 1 L/day, NaCl 3.6 g/day and furosemide 40 mg/day. Mean correction of 1.5 mmol/L/day and 80% serum sodium > 130 mmol/L at discharge, at the cost of hypokalemia (51%), hypomagnesemia (29.5%) and AKI (18.2%).

■ AKI and critical care
FRENSHOCK multicenter registry (772 patients): 15% needed acute dialysis, associated with roughly three times higher 30-day mortality. Neither timing of initiation nor modality significantly changes prognosis.